Appraisal consultation

You can now comment on this draft guidance.

How to comment

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments.


We have a new way of making comments on this consultation. You must make your comments directly onto the online version of the consultation document. When you go into the document you will find instructions on how to use the new commenting software. You can also review and edit your comments before you submit them.


You can download a PDF version of the consultation document, but you can only make comments on the online version.

Consultation document

Closing date for comments: 5:00pm, 26 April 2021

About the consultation

We have asked some questions about the consultation that we would like you to answer. You will be able to see the questions when you go into the online consultation document. 

 We would also like you to think about whether there are any aspects of the recommendations that need particular consideration to make sure we avoid unlawful discrimination against any group of people. For example, on the grounds of:

  • race
  • gender
  • disability
  • religion or belief
  • sexual orientation
  • age
  • gender reassignment
  • pregnancy and maternity.

Note that this document is not NICE's final guidance on this technology. The recommendations in section 1 may change after consultation.

After the consultation has closed the appraisal committee will meet again to consider the responses received and prepare the final appraisal document.


Providing comments on the updated scope

Section 6.2 of NICE’s Guide to the methods of technology appraisal states that the committee must make judgements on the appropriateness and relevance of comparator technologies because this is crucial to the consideration of the clinical and cost-effectiveness evidence. When selecting the most appropriate comparator(s), the committee considers several factors including established NHS practice in England and existing NICE guidance. During the first committee meeting, the clinical experts and clinical lead for the Cancer Drugs Fund highlighted that the version of the scope that was disseminated at the start of the appraisal no longer accurately represented established NHS practice (for further details, see section 3.3 of the ACD). The scope has therefore been updated and reissued with the consultation documents.

NICE would like to invite comments on the updated scope. Please submit these comments alongside any comments on the ACD.

Find out more


This page was last updated: